Dyslipidemia

Population Health Data May Help Identify Patients at Risk for CVD

Population Health Data May Help Identify Patients at Risk for CVD

Population-level data can help medical practitioners use electronic health records to identify patients at risk for cardiovascular disease.

High-Intensity Statins Affect Coronary Plaque Composition After STEMI

High-Intensity Statins Affect Coronary Plaque Composition After STEMI

By

Patients using a high-intensity statin after a STEMI experienced a significant increase in minimum fibrous cap thickness.

Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective

Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective

By

For alirocumab to be considered cost-effective compared with generic ezetimibe, its annual price would have to be reduced to less than $90.

Cardiovascular Disease Risk Factors in Heterozygous Familial Hypercholesterolemia

Cardiovascular Disease Risk Factors in Heterozygous Familial Hypercholesterolemia

By

Smoking, hypertension, and diabetes contributed to more than a quarter of excess CVD risk in individuals with heterozygous familiar hypercholesterolemia.

Ultrasonography and MRI May Improve Diagnosis of Achilles Tendon Xanthoma in FH

Ultrasonography and MRI May Improve Diagnosis of Achilles Tendon Xanthoma in FH

By

Ultrasonography or MRI may improve diagnosis of ATX in familial hypercholesterolemia, identifying patients at risk for more severe coronary artery disease.

Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look

Familial Hypercholesterolemia: An Underdiagnosed Disease Gets a Second Look

By

Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.

Robust LDL-C Reduction With Alirocumab in Patients Who Tolerate Only Lowest Statin Doses

Robust LDL-C Reduction With Alirocumab in Patients Who Tolerate Only Lowest Statin Doses

By

Hypercholesterolemic patients who tolerate only lowest-dose statin or non-statin lipid lowering therapy can achieve LDL-C reduction with alirocumab.

Long-Term Adherence to High-Intensity Statin/Ezetimibe Regimens Reduces CV Risks

Long-Term Adherence to High-Intensity Statin/Ezetimibe Regimens Reduces CV Risks

Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk.

Metabolic Syndrome Highly Prevalent in Patients With Plaque Psoriasis

Metabolic Syndrome Highly Prevalent in Patients With Plaque Psoriasis

By

Metabolic syndrome and psoriatic arthritis were highly prevalent comorbidities in patients with plaque psoriasis.

Ezetimibe Plus Statins Modestly Reduce Cardiovascular Disease Event Risk

Ezetimibe Plus Statins Modestly Reduce Cardiovascular Disease Event Risk

By

Ezetimibe combined with statin therapy showed modest or moderate benefits in reducing major CVD event risk.

AHA: Statin Benefits Outweigh Risks

AHA: Statin Benefits Outweigh Risks

By

The data showed a <0.1% risk of statin-induced muscle injury, including rhabdomyolysis, and a ~0.001% risk of serious hepatotoxicity. Statin-induced newly diagnosed diabetes mellitus was a ~0.2% risk per year of treatment, depending on baseline risk in the patients studied.

Statin Use May Improve Bone Microstructure in Women With Osteoporosis

Statin Use May Improve Bone Microstructure in Women With Osteoporosis

By

Statin use is associated with better cortical bone characteristics in older women with osteoporosis, but results are dependent upon the potency of the statins.

Digital Obesity Treatment in Primary Care May Help Disadvantaged Patients

Digital Obesity Treatment in Primary Care May Help Disadvantaged Patients

By

Socioeconomically challenged patients with obesity and elevated cardiovascular risk may benefit from digital obesity treatment combined with health system resources.

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

By

The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.

Alirocumab Well Tolerated and Effective in Patients With Statin Intolerance

Alirocumab Well Tolerated and Effective in Patients With Statin Intolerance

By

Researcher observed a much lower rate of discontinuations due to skeletal muscle events with alirocumab in the open-label extension trial compared with the double-blind parent study (3.2% vs 15.9%).

Simvastatin Improves Inflammation, Platelet Activation Markers in Primary Hypercholesterolemia

Simvastatin Improves Inflammation, Platelet Activation Markers in Primary Hypercholesterolemia

By

In patients with primary hypercholesterolemia, short-term treatment with simvastatin improved the lipid profile and exerted a beneficial effect on a wide range of proatherogenic and prothrombotic parameters.

Consensus Guidelines Reinforce Healthy Living for Lowering Cholesterol

Consensus Guidelines Reinforce Healthy Living for Lowering Cholesterol

A healthy lifestyle for lowering cholesterol should be emphasized for reducing cardiovascular risk across the life course.

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

By

Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.

Nonadherence, Discontinuation High in First Year of Statin Therapy

Nonadherence, Discontinuation High in First Year of Statin Therapy

First-year nonadherence and discontinuation are high among older adults prescribed statins.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Treatment Examined

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Treatment Examined

By

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

Lipidome Profiles Stratify Risk for Type 2 Diabetes

Lipidome Profiles Stratify Risk for Type 2 Diabetes

By

Early detection of lipidome characteristics could help identify the early onset of type 2 diabetes.

Lack of Evidence for Noncardiovascular Outcomes With Statin Use

Lack of Evidence for Noncardiovascular Outcomes With Statin Use

There is a lack of convincing evidence for an association between statin use and noncardiovascular disease outcomes.

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

By

Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.

Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities

Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities

By

Investigators analyze characteristics of participants with acquired partial lipodystrophy who developed severe metabolic abnormalities.

Genetic Testing Recommended for Familial Hypercholesterolemia

Genetic Testing Recommended for Familial Hypercholesterolemia

Genetic testing should become the standard of care for patients with definite or probable familial hypercholesterolemia.

Poststroke Statin Therapy Associated With Lower Risk for Osteoporosis, Fractures

Poststroke Statin Therapy Associated With Lower Risk for Osteoporosis, Fractures

By

A variety of underlying mechanisms may be attributed to the role of statins in preventing bone-related disorders.

High LDL in Young, Healthy Adults Leaves Them Vulnerable to CVD

High LDL in Young, Healthy Adults Leaves Them Vulnerable to CVD

Low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) ≥160 mg/dL are independently associated with increased relative risk of cardiovascular disease (CVD) mortality in a low-risk cohort.

Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

By

"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.

Vitamin D Independently, Inversely Tied to Total, HDL, LDL Cholesterol in Children

Vitamin D Independently, Inversely Tied to Total, HDL, LDL Cholesterol in Children

Serum 25-hydroxyvitamin D [25(OH)D] is independently and inversely associated with total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol in children.

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

Nutraceuticals May Benefit Patients Who Are Statin Intolerant

By

Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.

Sign Up for Free e-Newsletters



CME Focus